Transaction · 0001193125-26-393274

Trenor Cameron C. III

Trenor Cameron C. III, CMO, reported a transaction classified as grant at AN2 Therapeutics, Inc. involving 233333.000000 shares for an estimated $0.00. Reported holdings after the transaction were 233333.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
ANTXAN2 Therapeutics, Inc.
Trade date
Sep 15, 2026
Filing date
Sep 16, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded233k$0.00 per share
Holdings after233kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ANTX price since this filing

Daily closing prices, with the filing date and available return windows
ANTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +12.2%1w ago +12.0%1d ago +2.2%
Returns since7d -9.6%30d -36.7%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001193125-26-393274
Stock Option (right to by)
Transaction date
Sep 15, 2026
Filed Sep 16, 2026, 09:35 PM · 1d delay
Shares
233,333 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
233,333 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annua…

  2. F2

    The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to…

Original filing · 0001193125-26-393274
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ANTX